title: [Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation].
abstract: Sequential therapy consisting of methotrexate (MTX) and 5-FU was performed together with the administration of heparin and FOY in 10 cases of gastric cancer with disseminated intravascular coagulation (DIC) causing systemic bone metastasis. The ages of the subjects ranged from 29 to 65 years (median: 49 years) with systemic bone metastasis and bone marrow carcinosis observed in all cases. Histological types consisted of 6 cases of poorly differentiated adenocarcinoma, 2 cases of signet-ring cell carcinoma, and one case each of mucocellular and tubular adenocarcinoma. Therapy consisted of intravenous injection of 30 mg-100 mg/m2 (one case, 20 mg) of MTX followed three hours later by intravenous injection of 600 mg/m2 of 5-FU weekly. Determination of DIC was made in accordance with the DIC diagnostic standards of the Ministry of Health and Welfare, and determination of tumor effectiveness was based on gastric cancer handling codes.
  
  
  RESULTS
  PR was observed in 3 cases. Diffuse metastasis observed in the entire lung field disappeared in one case, while remarkable improvement was observed in systemic bone metastasis in scintigram findings for the other 2 cases. All 3 cases were able to be discharged. Reduction of DIC score and absence of pain were observed in 8 cases. Based on the above, aggressive implementation of this treatment method is suggested.
authors.affiliation: Dept. of Chemotherapy, Komagome Metropolitan Hospital, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Ibuka
authors.forename: K
authors.initials: K
authors.lastname: Imai
authors.forename: K
authors.initials: K
authors.lastname: Monma
authors.forename: N
authors.initials: N
authors.lastname: Sakaki
authors.forename: I
authors.initials: I
authors.lastname: Tabata
authors.forename: J
authors.initials: J
authors.lastname: Ishiwata
authors.forename: Y
authors.initials: Y
authors.lastname: Onozawa
authors.forename: T
authors.initials: T
authors.lastname: Ohno
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D004211:Disseminated Intravascular Coagulation / Q000150:complications* / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D016670:Gabexate / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D016670:Gabexate; D006493:Heparin; D005472:Fluorouracil; D008727:Methotrexate